Brief: Intelgenx Technologies Receives FDA PDUFA Date For Rizafilm®
22/11/2022 12:36
Nov 22 (Reuters) - Intelgenx Technologies Corp IGX.TO :
* INTELGENX RECEIVES FDA PDUFA DATE FOR RIZAFILM®
* INTELGENX TECHNOLOGIES CORP - FDA ASSIGNED PRESCRIPTION
DRUG
USER FEE ACT GOAL DATE OF APRIL 17, 2023 FOR COMPLETION OF
REVIEW OF RIZAFILM NDA
Source text for Eikon: ID:nGNX6C6xcF
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA